Brokerages Set Stantec Inc. (STN) Price Target at $36.28

Shares of Stantec Inc. (TSE:STN) (NYSE:STN) have received a consensus recommendation of “Hold” from the nine research firms that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is C$36.28.

Several research firms recently weighed in on STN. Laurentian decreased their target price on shares of Stantec from C$36.50 to C$34.50 in a research note on Friday, February 23rd. National Bank Financial cut shares of Stantec from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from C$39.00 to C$37.00 in a research note on Friday, February 23rd. CIBC decreased their target price on shares of Stantec from C$39.00 to C$36.00 in a research note on Friday, February 23rd. Desjardins decreased their target price on shares of Stantec from C$43.00 to C$39.00 in a research note on Friday, February 23rd. Finally, TD Securities decreased their target price on shares of Stantec from C$38.00 to C$36.00 and set a “hold” rating for the company in a research note on Friday, February 23rd.

How to Become a New Pot Stock Millionaire

In related news, Director Valentino Dimanno acquired 1,552 shares of Stantec stock in a transaction on Tuesday, February 27th. The stock was purchased at an average cost of C$32.20 per share, with a total value of C$49,974.40. Also, Director Russell Edward Wlad sold 10,000 shares of Stantec stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of C$35.57, for a total transaction of C$355,700.00. Insiders purchased 6,437 shares of company stock valued at $175,332 over the last three months.

TSE STN opened at C$31.22 on Thursday. Stantec has a 12-month low of C$30.24 and a 12-month high of C$37.13.

Stantec (TSE:STN) (NYSE:STN) last posted its quarterly earnings data on Thursday, February 22nd. The company reported C$0.32 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C$0.46 by C($0.14). Stantec had a net margin of 1.40% and a return on equity of 2.39%. The business had revenue of C$805.00 million during the quarter, compared to analyst estimates of C$861.63 million.

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Thursday, March 29th will be paid a $0.138 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This is a boost from Stantec’s previous quarterly dividend of $0.13. This represents a $0.55 annualized dividend and a dividend yield of 1.77%.

WARNING: “Brokerages Set Stantec Inc. (STN) Price Target at $36.28” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3341233/brokerages-set-stantec-inc-stn-price-target-at-36-28.html.

Stantec Company Profile

Stantec Inc is a provider of professional services in the area of infrastructure and facilities for clients in the public and private sectors. The Company’s operates through four segments Consulting Services-Canada, Consulting Services-United States, Consulting Services-Global and Construction Services.

Analyst Recommendations for Stantec (TSE:STN)

Receive News & Ratings for Stantec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stantec and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Logitech  Expected to Post Earnings of $0.26 Per Share
Logitech Expected to Post Earnings of $0.26 Per Share
Perrigo  Given a $105.00 Price Target by Canaccord Genuity Analysts
Perrigo Given a $105.00 Price Target by Canaccord Genuity Analysts
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics Stock Price
FTD Companies  Getting Somewhat Positive Press Coverage, Report Shows
FTD Companies Getting Somewhat Positive Press Coverage, Report Shows
Koovs  Stock Price Up 28.2%
Koovs Stock Price Up 28.2%
Rigel Pharmaceuticals   Shares Down 6.5%
Rigel Pharmaceuticals Shares Down 6.5%


© 2006-2018 Ticker Report. Google+.